首页> 外文期刊>Contraception >The evolution of combined oral contraception: improving the risk-to-benefit ratio.
【24h】

The evolution of combined oral contraception: improving the risk-to-benefit ratio.

机译:联合口服避孕药的发展:提高风险收益率。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Since its introduction in 1960, the combined oral contraceptive (COC) pill has become one of the most widely and frequently used methods of contraception worldwide. Although highly effective, early COC formulations were associated with significant adverse effects and unacceptable cardiovascular risk. Improvements in tolerability and safety have been achieved, without compromises in effectiveness, primarily via hormone dosage reductions and the development of several new progestins. Multiphasic COCs and extended-/continuous-cycle COCs have also been introduced, although the clinical advantages of these formulations vs. traditional COCs have yet to be established. Inclusion of natural estrogens such as estradiol valerate and 17beta-estradiol with selective progestins in new combinations that maintain good cycle control is the most recent evolutionary step designed to improve COC tolerability and safety. Vigorous research needs to continue to help guarantee that the unmet need for safe and effective contraception is satisfied in future generations.
机译:自1960年问世以来,口服避孕药(COC)组合药已成为全球范围内使用最广泛的避孕方法之一。尽管非常有效,但早期的COC制剂仍具有明显的不良反应和不可接受的心血管风险。主要通过减少激素剂量和开发几种新的孕激素,在不影响疗效的前提下实现了耐受性和安全性的改善。尽管尚未确定这些制剂相对于传统COC的临床优势,但也已经引入了多相COC和延长/连续循环COC。在保持良好的循环控制的新组合中,将天然雌激素(例如戊酸雌二醇和17β-雌二醇)与选择性孕激素结合在一起,是旨在改善COC耐受性和安全性的最新进化步骤。需要继续进行大量研究,以确保子孙后代能够满足对安全有效避孕的未满足需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号